Senti Biosciences (NASDAQ:SNTI) Shares Down 3.6% – Here’s What Happened

Senti Biosciences, Inc. (NASDAQ:SNTI)’s share price was down 3.6% during trading on Wednesday . The company traded as low as $1.03 and last traded at $1.06. Approximately 75,015 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 172,147 shares. The stock had previously closed at $1.10.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Chardan Capital boosted their price objective on Senti Biosciences from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, May 15th. Wall Street Zen raised Senti Biosciences from a “strong sell” rating to a “hold” rating in a report on Saturday, March 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Senti Biosciences has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Senti Biosciences Stock Performance

The business’s 50-day moving average price is $0.99 and its 200 day moving average price is $0.99. The stock has a market capitalization of $33.33 million, a PE ratio of -0.56 and a beta of 2.04.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.22. The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.02 million. As a group, equities research analysts predict that Senti Biosciences, Inc. will post -1.53 earnings per share for the current year.

Institutional Trading of Senti Biosciences

A number of large investors have recently modified their holdings of the business. Jane Street Group LLC purchased a new position in shares of Senti Biosciences during the fourth quarter worth about $40,000. Virtu Financial LLC bought a new stake in Senti Biosciences during the fourth quarter valued at approximately $46,000. Citadel Advisors LLC bought a new stake in Senti Biosciences during the third quarter valued at approximately $117,000. Geode Capital Management LLC grew its stake in Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares in the last quarter. Finally, Armistice Capital LLC purchased a new position in Senti Biosciences in the 2nd quarter worth approximately $1,883,000. Institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.